8-K: Viskase Holdings Appoints Grant Thornton as Auditor

Sentiment:

Change in Certifying Accountant


Viskase Holdings, Inc. has appointed Grant Thornton LLP as its new independent registered public accounting firm following its recent merger.

Summary

  • Viskase Holdings, Inc. (formerly Enzon Pharmaceuticals) appointed Grant Thornton LLP as its independent auditor on April 14, 2026.
  • The appointment follows the company's merger with Viskase Companies, Inc., which was consummated on March 26, 2026.
  • EisnerAmper LLP, the former auditor, was dismissed effective April 15, 2026.
  • The transition is standard procedure following a corporate merger to align the auditor with the surviving entity's previous accounting firm.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, administrative event typical of post-merger integration.

Positives

  • The change in auditors is a routine administrative step following a merger, ensuring continuity with the firm that previously audited Viskase Companies, Inc.
  • There were no disagreements or reportable events between the company and the former auditor, EisnerAmper LLP, during the relevant periods.
  • EisnerAmper LLP confirmed in a letter to the SEC that they agree with the company's disclosures regarding the change.

Negatives

  • The engagement of Grant Thornton remains subject to the satisfactory completion of standard client acceptance procedures.

Risks

  • Potential for minor administrative delays or costs associated with the transition of audit services between firms.

Future Outlook

The company intends to utilize Grant Thornton LLP to audit its consolidated financial statements for the fiscal year ending December 31, 2026.

Industry Context

StockSavvy.ai notes that auditor changes are standard practice following M&A activity to consolidate financial reporting under a single firm, particularly when one entity in the merger is significantly larger or has an established relationship with a specific auditor.

Comparison to Industry Standards

  • The disclosure follows standard SEC requirements under Item 4.01 of Form 8-K.
  • The absence of disagreements with the outgoing auditor is consistent with best practices for a clean transition.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Auditor AppointmentAppointment of Grant Thornton LLP as independent registered public accounting firm.2026-04-14Ensures audit continuity following the merger.

Stakeholder Impact

  • Shareholders should expect standard audit procedures to continue under the new firm.

Next Steps

  • Completion of client acceptance procedures by Grant Thornton LLP.
  • Commencement of the audit for the fiscal year ending December 31, 2026.

Key Dates

DateDescription
2025-06-20Date of the Agreement and Plan of Merger.
2026-03-26Consummation of the merger between Enzon Pharmaceuticals and Viskase Companies, Inc.
2026-04-14Audit Committee appointment of Grant Thornton LLP.
2026-04-15Dismissal of EisnerAmper LLP as independent auditor.
2026-04-16Date of the letter from EisnerAmper LLP to the SEC confirming agreement with the filing.

Keywords

Viskase Holdings, Auditor Change, Grant Thornton, EisnerAmper, Merger, SEC Filing, Corporate Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.